SCHEMBL608873

SCHEMBL608873

CC(O)=CC(=O)C=Cc1ccc(N(C)C)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 1/20 0.74
MAPT P10636 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
KMT2A Q03164 2/20 0.54
CASP3 P42574 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CYP1B1 Q16678 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
TLR9 Q9NR96 2/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
FOS P01100 1/20 0.51
JUN P05412 1/20 0.51
MAOB P27338 3/20 0.50
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608872 1.00 HSD17B3 (0.74) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL607704 0.88 HSD17B3 (0.77) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL607705 0.88 HSD17B3 (0.77) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL3050207 0.86 HSD17B3 (1.00) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL814396 0.86 HSD17B3 (1.00) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL814395 0.86 HSD17B3 (1.00) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL11319298 0.83 HSD17B3 (0.86) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL11319313 0.83 HSD17B3 (0.86) HSD17B3MAPTNPC1RAB9AKMT2A
SCHEMBL30851343 0.81 GSK3B (0.73) MAPTRAB9AKMT2ACASP3SMN1; SMN2
SCHEMBL29045953 0.81 HSD17B3 (0.82) HSD17B3MAPTNPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281649-A1 PROBE DIRECTED TO ENZYME ALDH1A3 AND USE THEREOF IN THE DIAGNOSIS OF GLIOBLASTOMA UNIV DEGLI STUDI DEL PIEMONTE ORIENTALE A AVOGADRO (IT) 2025-09-11 US disclosed
EP-4320194-A1 PROBE DIRECTED TO ENZYME ALDH1A3 AND USE THEREOF IN THE DIAGNOSIS OF GLIOBLASTOMA Università degli Studi del Piemonte Orientale "Amedeo Avogadro" (IT) 2024-02-14 EP disclosed
US-11596716-B2 Compounds and matrices for use in bone growth and repair HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2023-03-07 US disclosed
WO-2022214995-A1 PROBE DIRECTED TO ENZYME ALDH1A3 AND USE THEREOF IN THE DIAGNOSIS OF GLIOBLASTOMA UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO" (IT) 2022-10-13 WO disclosed
US-20210138117-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2021-05-13 US disclosed
US-10874766-B2 Compounds and matrices for use in bone growth and repair HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2020-12-29 US disclosed
EP-3038621-B1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RES INSTITUTE (US) 2020-12-02 EP disclosed
EP-3038621-A2 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR Human Biomolecular Research Institute (US) 2016-07-06 EP disclosed
US-20160038641-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2016-02-11 US disclosed
WO-2014146039-A2 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2014-09-18 WO disclosed
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-02-16 US disclosed
WO-2010068935-A2 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874766-B2 Compounds and matrices for use in bone growth and repair BMP2, BMP4, BMP6 HSD17B3 2608/4885MAPT 4729/4885NPC1 4676/4885
US-11596716-B2 Compounds and matrices for use in bone growth and repair BMP2, BMP4, BMP6 HSD17B3 2143/4885MAPT 4739/4885NPC1 4454/4885
US-20210138117-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR BMP2, BMP4, BMP6 HSD17B3 2143/4885MAPT 4739/4885NPC1 4454/4885
US-20250281649-A1 PROBE DIRECTED TO ENZYME ALDH1A3 AND USE THEREOF IN THE DIAGNOSIS OF GLIOBLASTOMA ALDH3A1, ALDH1A3, ALDH1A1 HSD17B3 30/4885MAPT 3189/4885NPC1 3077/4885
US-20160038641-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR BMP2, BMP4, BMP6 HSD17B3 3186/4885MAPT 4725/4885NPC1 4677/4885
US-20120040976-A1 SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE L1CAM, LY96, GMFG HSD17B3 4468/4885MAPT 8/4885NPC1 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.